BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Jan. 4, 2002
View Archived Issues
BioCryst Gets Flu Drug Back On Track, Resumes Enrollment
BioCryst Pharmaceuticals Inc. started out the flu season earlier this week by commencing Phase III enrollment in the United States for its flu treatment, peramivir, after getting clearance from the FDA to resume the study.
Read More
Neurocrine, Taisho Start Pivotal Study Of Diabetes Candidate
Read More
Too Much p53 Tumor Suppressor Activity Hastens Symptomatology Of Advanced Senescence In Mice
Read More
Rib-X Raises $22M In Series A To Develop Anti-Infective Drugs
Read More
Other News To Note
Read More